- Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results
- Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress
- Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024
- UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
- Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy
- Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets
- Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
- Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication
- Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy
- Ocugen Provides Business Update with Certain Financials for the Year Ending 2023
More ▼
Key statistics
On Friday, Ocugen Inc (OCGN:NAQ) closed at 1.33, -36.82% below its 52-week high of 2.11, set on Mar 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.36 |
---|---|
High | 1.42 |
Low | 1.32 |
Bid | 1.34 |
Offer | 1.36 |
Previous close | 1.32 |
Average volume | 6.16m |
---|---|
Shares outstanding | 257.33m |
Free float | 253.60m |
P/E (TTM) | -- |
Market cap | 342.24m USD |
EPS (TTM) | -0.2616 USD |
Data delayed at least 15 minutes, as of May 03 2024 21:00 BST.
More ▼